124 related articles for article (PubMed ID: 21271224)
1. Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: correlation of protein expression and GC/TOF-MS-based metabolomics.
Buckendahl AC; Budczies J; Fiehn O; Darb-Esfahani S; Kind T; Noske A; Weichert W; Sehouli J; Braicu E; Dietel M; Denkert C
Oncol Rep; 2011 Apr; 25(4):1005-12. PubMed ID: 21271224
[TBL] [Abstract][Full Text] [Related]
2. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
4. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
[TBL] [Abstract][Full Text] [Related]
5. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy.
Wen YH; Yee H; Goswami S; Shukla PS
Int J Gynecol Pathol; 2009 Mar; 28(2):187-92. PubMed ID: 19188814
[TBL] [Abstract][Full Text] [Related]
6. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
[TBL] [Abstract][Full Text] [Related]
7. [Expression and clinical relevance of ARHI, STAT3 and E2F1 in ovarian serous carcinoma].
Zhang J; Li YH; Cui AR; Wang JL; Cheng JX; Wang SJ
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):905-9. PubMed ID: 19173990
[TBL] [Abstract][Full Text] [Related]
8. [Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma].
Zhang MZ; Qiao YH; Suo ZH
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):848-52. PubMed ID: 19173831
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
10. [Expression and significance of GLUT-1 and DNA-PKcs in serous ovarian tumors].
Cai Y; Shao SL; Wang QH; Yan LJ; Wang XY; Wang LX
Ai Zheng; 2007 Nov; 26(11):1188-93. PubMed ID: 17991316
[TBL] [Abstract][Full Text] [Related]
11. The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced-stage ovarian carcinoma.
Ødegaard E; Staff AC; Abeler VM; Kopolovic J; Onsrud M; Lazarovici P; Davidson B
Hum Pathol; 2007 Jan; 38(1):140-6. PubMed ID: 16996570
[TBL] [Abstract][Full Text] [Related]
12. Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma.
Wang X; Wei Z; Gao F; Zhang X; Zhou C; Zhu F; Wang Q; Gao Q; Ma C; Sun W; Kong B; Zhang L
Anticancer Res; 2008; 28(5B):2991-6. PubMed ID: 19031945
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
[TBL] [Abstract][Full Text] [Related]
14. Expression of Fas and FasL in human serous ovarian epithelial tumors.
van Haaften-Day C; Russell P; Davies S; King NJ; Tattersall MH
Hum Pathol; 2003 Jan; 34(1):74-9. PubMed ID: 12605369
[TBL] [Abstract][Full Text] [Related]
15. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
Borgoño CA; Kishi T; Scorilas A; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
Clin Cancer Res; 2006 Mar; 12(5):1487-93. PubMed ID: 16533772
[TBL] [Abstract][Full Text] [Related]
16. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors.
Denkert C; Budczies J; Kind T; Weichert W; Tablack P; Sehouli J; Niesporek S; Könsgen D; Dietel M; Fiehn O
Cancer Res; 2006 Nov; 66(22):10795-804. PubMed ID: 17108116
[TBL] [Abstract][Full Text] [Related]
17. Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.
Bolat F; Gumurdulu D; Erkanli S; Kayaselcuk F; Zeren H; Ali Vardar M; Kuscu E
Pathol Res Pract; 2008; 204(6):379-87. PubMed ID: 18343598
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
19. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
[TBL] [Abstract][Full Text] [Related]
20. Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis.
Noske A; Lindenberg JL; Darb-Esfahani S; Weichert W; Buckendahl AC; Röske A; Sehouli J; Dietel M; Denkert C
Oncol Rep; 2008 Dec; 20(6):1409-17. PubMed ID: 19020722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
